Key Takeaways
- Novo Nordisk is preparing to submit its oral Wegovy formulation for Chinese approval in the coming months
- New CEO Mike Doustdar revealed the timeline during his inaugural China visit following his August appointment
- Eli Lilly has already filed orforglipron with Chinese authorities in late 2025, establishing first-mover advantage
- China’s semaglutide patent lapsed in March, opening doors for generic manufacturers from the second quarter of 2026
- NVO stock trades with a Hold rating from analysts, showing modest 0.09% gains with a $46 price target
Novo Nordisk is accelerating its entry into China’s expanding oral obesity treatment sector, with Chief Executive Mike Doustdar declaring the company will pursue regulatory clearance for its pill-based Wegovy formulation “very soon — a few months.”
Doustdar disclosed this timeline while visiting China for the first time since assuming leadership in August. At the time of his statement, NVO stock showed a marginal 0.09% increase.
China represents the globe’s second-biggest pharmaceutical marketplace, with GLP-1 obesity medications emerging as a particularly dynamic category. First-quarter GLP-1 sales through e-commerce giants Alibaba and JD.com reached approximately 1.4 billion yuan ($207 million), based on Jefferies research.
Novo has established initial market presence. Chinese regulators approved its injectable Wegovy in mid-2024. A tablet alternative would expand the company’s reach, appealing to consumers who favor oral medications over injections.
However, the Danish drugmaker trails its American rival. Eli Lilly filed its daily oral medication orforglipron with Chinese authorities in December 2025, securing an earlier position in the regulatory pipeline. Lilly currently sells Mounjaro throughout China for both diabetes management and weight reduction.
Patent Expiration Creates New Challenges
Competitive threats extend beyond Lilly. Semaglutide — the core compound in Wegovy and Ozempic — shed its Chinese patent shield in March. While Novo maintains regulatory data exclusivity through early next year, generic alternatives are projected to emerge by the second quarter of 2026.
Doustdar recognized this challenge while highlighting production complexity as a protective factor. “Not many of our competitors will be able to reach that level, have the capabilities,” he stated, emphasizing the difficulty of manufacturing the oral version at commercial volumes.
To maintain competitiveness against generic producers and domestic alternatives, Novo has implemented price reductions for Wegovy across select Chinese regions.
Pfizer and domestic company Innovent Biologics have similarly joined the marketplace, though precise market distribution data for China remains limited. Neither Innovent nor Lilly publishes China-specific revenue figures.
Novo introduced its Wegovy tablet in American markets this year after securing early regulatory clearance in both the United States and United Kingdom. Lilly obtained U.S. authorization for orforglipron in April.
Analyst Perspective
According to Wall Street assessment, NVO maintains a Hold consensus through three identical Hold recommendations on TipRanks. The mean price objective stands at $46, suggesting approximately 4.7% potential appreciation from present trading levels.
Throughout the current year, NVO has declined 11.4%, demonstrating investor concerns regarding patent vulnerabilities, pricing dynamics, and intensifying market competition.
The China regulatory submission is anticipated within the next several months, per Doustdar’s indication.
